Michael Pfreundschuh

45.0k total citations · 8 hit papers
421 papers, 20.6k citations indexed

About

Michael Pfreundschuh is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology. According to data from OpenAlex, Michael Pfreundschuh has authored 421 papers receiving a total of 20.6k indexed citations (citations by other indexed papers that have themselves been cited), including 233 papers in Pathology and Forensic Medicine, 153 papers in Oncology and 123 papers in Immunology. Recurrent topics in Michael Pfreundschuh's work include Lymphoma Diagnosis and Treatment (225 papers), Chronic Lymphocytic Leukemia Research (111 papers) and Monoclonal and Polyclonal Antibodies Research (91 papers). Michael Pfreundschuh is often cited by papers focused on Lymphoma Diagnosis and Treatment (225 papers), Chronic Lymphocytic Leukemia Research (111 papers) and Monoclonal and Polyclonal Antibodies Research (91 papers). Michael Pfreundschuh collaborates with scholars based in Germany, United States and Switzerland. Michael Pfreundschuh's co-authors include Uğur Şahin, Markus Loeffler, Özlem Türeci, Norbert Schmitz, Marita Ziepert, Lorenz Trümper, Lloyd J. Old, Volker Diehl, Yao‐Tseng Chen and Samira Zeynalova and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Michael Pfreundschuh

407 papers receiving 20.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

1997 1.0k citations Uğur Şahin, Özlem Türeci et al. profile →
Human neoplasms elicit multiple specific immune responses in the autologous host.

1995 896 citations Uğur Şahin, Rudolf Schmits et al. profile →
A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

2007 621 citations Martin Dreyling, Michael Pfreundschuh et al. Blood profile →
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2015 611 citations Michael Pfreundschuh et al. Annals of Oncology profile →
Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin's Disease

2003 538 citations Volker Diehl, Jeremy Franklin et al. profile →
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL

2004 502 citations Michael Pfreundschuh Blood profile →
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma

2013 372 citations Heike Horn, Marita Ziepert et al. Blood profile →
Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

2016 280 citations Andreas Viardot, Michael Pfreundschuh et al. Blood profile →

Peers

Countries citing papers authored by Michael Pfreundschuh

Since Specialization

Citations

This map shows the geographic impact of Michael Pfreundschuh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Pfreundschuh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Pfreundschuh more than expected).

Fields of papers citing papers by Michael Pfreundschuh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Pfreundschuh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Pfreundschuh. The network helps show where Michael Pfreundschuh may publish in the future.

Co-authorship network of co-authors of Michael Pfreundschuh

This figure shows the co-authorship network connecting the top 25 collaborators of Michael Pfreundschuh. A scholar is included among the top collaborators of Michael Pfreundschuh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael Pfreundschuh. Michael Pfreundschuh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Impact of vincristine dose reduction on outcomes of patients with aggressive B-cell lymphoma treated with (R)-CHOP 2023 ·Haematologica ·Moritz Bewarder, Dominic Kaddu‐Mulindwa, Igor Age Kos, (unknown), Gerhard Held, Viola Poeschel, Lorenz Thurner, Joerg Thomas Bittenbring, Norbert Schmitz, Lorenz Truemper, Michael Pfreundschuh, Konstantinos Christofyllakis, Markus Loeffler, Bettina Altmann, Marita Ziepert	2
2	FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials 2021 ·European Journal of Nuclear Medicine and Molecular Imaging ·Dominic Kaddu‐Mulindwa, Bettina Altmann, Gerhard Held, (unknown), Stephan Stilgenbauer, Lorenz Thurner, Moritz Bewarder, (unknown), Michael Pfreundschuh, Markus Löffler, Karin Menhart, Jirka Grosse, Marita Ziepert, Ken Herrmann, Ulrich Dührsen, Andreas Hüttmann, Francesco Barbato, Viola Poeschel, D. Hellwig	20
3	VEGFR2 and VEGFA polymorphisms are not associated with an inferior prognosis in Caucasian patients with aggressive B‐cell lymphoma 2020 ·European Journal Of Haematology ·Dominic Kaddu‐Mulindwa, Maciej Rosołowski, Marita Ziepert, Evi Regitz, G. Aßmann, Moritz Bewarder, Gerhard Held, Michael Pfreundschuh, Joerg Thomas Bittenbring	4
4	High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology 2018 ·Blood ·David W. Scott, Rebecca L. King, Annette M. Staiger, Susana Ben‐Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W. Slack, Daisuke Ennishi, Norbert Schmitz, Michael Pfreundschuh, Grzegorz S. Nowakowski, Brad S. Kahl, Joseph M. Connors, Randy D. Gascoyne, German Ott, William R. Macon, Andreas Rosenwald	145
5	Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis 2015 ·Annals of Oncology ·Isabelle Fleury, Sylvie Chevret, Michael Pfreundschuh, Gilles Salles, Bertrand Coiffier, Marinus H. J. van Oers, C Gisselbrecht, Emanuele Zucca, Michael Herold, Michele Ghielmini, Catherine Thiéblemont	49
6	Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group 2014 ·Journal of Clinical Oncology ·Michael Pfreundschuh, Viola Poeschel, Samira Zeynalova, Mathias Hänel, Gerhard Held, Norbert Schmitz, Andreas Viardot, Martin Dreyling, Michael Hallek, (unknown), Martin H. J. Wiesen, Mathias Witzens‐Harig, Lorenz Truemper, Ulrich Keller, Tanja Rixecker, Carsten Zwick, Niels Murawski	59
7	Validation of a Prognostic Model to Assess the Risk of CNS Disease in Patients with Aggressive B-Cell Lymphoma 2014 ·Blood ·Kerry J. Savage, Samira Zeynalova, Roopesh Kansara, Maike Nickelsen, Diego Villa, Laurie H. Sehn, Marita Ziepert, David W. Scott, Michael Pfreundschuh, Randy D. Gascoyne, Joseph M. Connors, Bertram Glaß, Markus Loeffler, Norbert Schmitz	19
8	Circulating Levels of TNF Receptor II Are Prognostic for Patients with Peripheral T-cell Non–Hodgkin Lymphoma 2012 ·Clinical Cancer Research ·(unknown), Markus Kreuz, (unknown), Nils Schoof, Frederike von Bonin, Marita Ziepert, Markus Löffler, Wolfram Jung, Michael Pfreundschuh, Lorenz Trümper, Dieter Kube	32
9	Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group 2010 ·Blood ·Norbert Schmitz, Lorenz Trümper, Marita Ziepert, Maike Nickelsen, Anthony D. Ho, Bernd Metzner, Norma Peter, Markus Loeffler, Andreas Rosenwald, Michael Pfreundschuh	377
10	CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) 2009 ·Blood ·(unknown), Norbert Schmitz, Samira Zeynalova, Markus Loeffler, Michael Pfreundschuh	194
11	Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study 2009 ·Journal of Clinical Oncology ·Andreas Engert, Volker Diehl, Jeremy Franklin, Andreas Lohri, Bernd Dörken, Wolf‐Dieter Ludwig, P. Koch, Mathias Hänel, Michael Pfreundschuh, Martin Wilhelm, Lorenz Trümper, (unknown), Martin Bentz, Mathias Rummel, Orhan Sezer, Hans–Konrad Müller–Hermelink, Dirk Hasenclever, Markus Löffler	303
12	Targeted Bioactivity of Membrane-Anchored TNF by an Antibody-Derived TNF Fusion Protein 2004 ·The Journal of Immunology ·Stefan Bauer, Nicole Adrian, Barbara Williamson, Con Panousis, Natalie Fadle, (unknown), (unknown), Andrew M. Scott, Michael Pfreundschuh, Christoph Renner	37
13	2-weekly vs 3-weekly CHOP with and without Etoposide in Young Patients with Low-Risk Aggressive Non-Hodgkins Lymphoma Results of the Completed NHL-B-1 Trial of the DSHNHL 2002 ·Blood ·Michael Pfreundschuh, Lorenz Truemper, Rudolf Schmits, Marita Kloess, (unknown), B. Glaß, Christian Rudolph, Andreas Engert, (unknown), D Hossfeld, Markus Loeffler, (unknown)	1
14	Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma 2002 ·The Journal of Immunology ·Maha Ayyoub, Stefan Stevanović, Uğur Şahin, Philippe Guillaume, Catherine Servis, Donata Rimoldi, Danila Valmori, Pedro Romero, Jean‐Charles Cerottini, Hans‐Georg Rammensee, Michael Pfreundschuh, Daniel E. Speiser, Frédéric Lévy	100
15	Assessment of clonality of rosetting T lymphocytes in Hodgkin's disease by single-cell polymerase chain reaction: detection of clonality in a polyclonal background in a case of lymphocyte predominance Hodgkin's disease 2001 ·Annals of Hematology ·(unknown), W. Jung, H. Daus, Gunhild Mechtersheimer, Florian Bonin, Michael Pfreundschuh	6
16	Exploitation of the Antibody Repertoire of Cancer Patients for the Identification of Human Tumor Antigens 1999 ·Hybridoma ·Özlem Türeci, Uğur Şahin, C. Zwick, Frank Neumann, Michael Pfreundschuh	46
17	A young woman with a photosensitive pruritic rash on her face and upper trunk 1996 ·Arthritis & Rheumatism ·(unknown), Stefan John, Michael Pfreundschuh, Angela Gause	9
18	Treatment of Heterotransplanted Hodgkin's Tumors in SCID Mice by a Combination of Human NK or T Cells and Bispecific Antibodies 1995 ·Journal of Hematotherapy ·Christoph Renner, Michael Pfreundschuh	12
19	Hodgkin's disease in adults preliminary results of the hd 1 hd 2 and hd 3 trials 1986 ·Journal of Cancer Research and Clinical Oncology ·Volker Diehl, Michael Pfreundschuh, (unknown), Markus Loeffler, (unknown), A. Georgii, (unknown)	1
20	Sensitive radioimmunoassay for thyrotropin by use of commercially available tracer and antibody. 1977 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Michael Pfreundschuh, M. Hüfner	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact